Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma

Abstract Purpose Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Despite the use of aggressive combination chemotherapy regimens, outcomes remain unsatisfactory. Schlafen family member 11 (SLFN11) has been reported to regulate the DNA damage response and influence tumor sensitivity to...

Full description

Bibliographic Details

Published in:	Journal of Cancer Research and Clinical Oncology
Main Authors:	Takeaki Nakamura, Kanako C. Hatanaka, Yasuyuki Kawamoto, Shiho Kaneko, Koichi Ishida, Kazuaki Harada, Satoshi Yuki, Yoshito Komatsu, Yutaka Hatanaka, Naoya Sakamoto
Format:	Article
Language:	English
Published:	Springer 2025-05-01
Subjects:	Pancreatic ductal adenocarcinoma SLFN11 Immunohistochemistry Chemotherapy Biomarker Prognosis
Online Access:	https://doi.org/10.1007/s00432-025-06216-8